Shares of Fulcrum Therapeutics, Inc. (FULC) have traded between $4.37 – 22.96. The next earnings date is set for Feb 13, 2020. Let’s see how its prospects are shaping up.
What does Fulcrum Therapeutics, Inc.(FULC) do?
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
FULC Insider Trading Insight
On 2019-07-22, Sanofi 10% purchased 93,750 shares of FULC. That represents a value of $558,035. Not to be outdone, on 2019-07-22, Third Rock Ventures Iv, L.P. P – Purchase bought81,250 shares of FULC. These insiders are clearly in the know because they work closely with the company.
The EV Consensus Price Target
The mean recommendation of Eaton Vance Corp. from top Wall Street analysts is a Hold. That is based on 4 analysts who work on the Street. Based on 4 analysts offering 12 month price targets for Eaton Vance in the last 3 months. The average price target is $46.75 with a high forecast of $49.00 and a low forecast of $45.00. The average price target represents a -1.68% decrease from the last price of $47.55. Last week, several articles were published in financial papers about EV and 38% Bearish while 62% Bullish.
EV Intraday Trading
EV is due to report earnings on Feb 25, 2020. In the last year the price has ranged from 35.85 – 48.98. Recently, Faust Thomas E Jr sold 54,577 shares of EV. He is a $556,587 shareholder in EV.